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Highlights: 
• 4-week mouse inhalation study with 0%, 27% and 78% Zr-doped CeO2 nanoparticles 
• No acceleration of Alzheimer-related features in 5xFAD mouse model 
• Motor performance changes in 78% Zr-doped CeO2 exposed ApoE-/- and 5xFAD mice 
• Increased GFAP levels in 78% Zr-doped CeO2 exposed C57BL/6J mice 
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ABSTRACT 
Increasing evidence from toxicological and epidemiological studies indicates that the brain is 
an important target for ambient (ultrafine) particles. Disturbance of redox-homeostasis and 
inflammation in the brain are proposed as possible mechanisms that can contribute to 
neurotoxic and neurodegenerative effects. Whether and how engineered nanoparticles (NPs) 
may cause neurotoxicity and promote neurodegenerative diseases such as Alzheimer´s disease 
(AD) is largely unstudied. 
We have assessed the neurological effects of subacute inhalation exposures (4 mg/m3 
for 3 h/day, 5 days/week for 4 weeks) to cerium dioxide (CeO2) NPs doped with different 
amounts of zirconium (Zr, 0%, 27% and 78%), to address the influence of particle redox-
activity in the 5xFAD transgenic mouse model of AD. Four weeks post-exposure, effects on 
behaviour were evaluated and brain tissues were analysed for amyloid-β plaque formation and 
reactive microglia (Iba-1 staining). Behaviour was also evaluated in concurrently exposed 
non-transgenic C57BL/6J littermates, as well as in Western diet-fed apolipoprotein E-
deficient (ApoE-/-) mice as a model of vascular disease. Markers of inflammation and 
oxidative stress were evaluated in brain cortex. 
The brains of the NP-exposed 5xFAD mice revealed no accelerated amyloid-β plaque 
formation. No significant treatment-related behaviour impairments were observed in the 
healthy C57BL/6J mice. In the 5xFAD and ApoE-/- models, the NP inhalation exposures did 
not affect the alternation score in the X-maze indicating absence of spatial working memory 
deficits. However, following inhalation exposure to the 78% Zr-doped CeO2 NPs changes in 
forced motor performance (string suspension) and exploratory motor activity (X-maze) were 
observed in ApoE-/- and 5xFAD mice, respectively. Exposure to the 78% doped NPs also 
caused increased cortical expression of glial fibrillary acidic protein (GFAP) in the C57BL/6J 
mice. No significant treatment-related changes neuroinflammation and oxidative stress were 
observed in the 5xFAD and ApoE-/- mice. 
Our study findings reveal that subacute inhalation exposure to CeO2 NPs does not 
accelerate the AD-like phenotype of the 5xFAD model. Further investigation is warranted to 
unravel whether the redox-activity dependent effects on motor activity as observed in the 
mouse models of AD and vascular disease result from specific neurotoxic effects of these 
NPs. 
 
Keywords: Cerium dioxide, Nanoparticles, Inhalation, Alzheimer’s disease, Amyloid-β 
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1. INTRODUCTION  
 
Several research groups have postulated that ultrafine air pollution particles are an important 
environmental risk factor for neurotoxicity and, more specifically, may potentiate the risk of 
neurodegenerative disorders, like Alzheimer’s Disease (AD) (reviewed in (Heusinkveld et al. 
2016). In relation to this, concerns have been raised about the potential neurotoxic and 
neurodegenerative effects of engineered nanoparticles (NPs). However, despite great progress 
in nanotechnologies, comparatively little is known to date on the potential adverse effects that 
exposure to manufactured NPs may have on the human brain, including the potential 
induction of pathways leading to neurodegeneration (Cupaioli et al. 2014). Indeed, NPs can 
enter the human body through several routes, e.g. via inhalation, absorption from the digestive 
tract, or following injection into the blood in nanomedical applications. With regard to 
potential adverse impacts on the brain, uptake and retrograde axonal transport of NPs via the 
olfactory nerve has been demonstrated in rodent inhalation studies (Oberdorster et al. 2004; 
Elder et al. 2006; Elder and Oberdorster 2006). Besides, NPs may reach the central nervous 
system via the blood–brain barrier (BBB), where they have been suspected to impair several 
molecular pathways and contribute to neurodegeneration (Iqbal et al. 2013; Cupaioli et al. 
2014). The ability to generate reactive oxygen species and associated inflammation is 
considered one of the key mechanisms of nanomaterials´ toxicity to the respiratory tract and 
cardiovascular system (Unfried et al.     2008; Miller, Shaw, and Langrish 2012; Stone et al.     
2017) and thus could also play a major role in their neurotoxic and neurodegenerative effects. 
Indeed, oxidative stress and neuroinflammation have long been recognised in neurotoxicity 
and neurodegenerative diseases including AD (Heneka et al.     2015; Zhao and Zhao 2013). 
 Among the various types of NPs, cerium oxide NPs (CeO2 NPs) have been subjected 
to various toxicological investigations in relation to inhalation exposure (Cassee et al.     
2011; Demokritou et al.     2013). CeO2 NPs are widely used as catalysts in industrial 
applications. They are used as additive to diesel fuels in order to reduce the amount of emitted 
pollutants after their combustion. Because of their radical-scavenging properties, CeO2 NPs 
have gained strong interest in the field of nanomedicine (reviewed in (Das et al. 2013)). The 
antioxidant properties of CeO2 NPs are accomplished through its ability to switch from the 3+ 
to the 4+ valence state (Hirst et al. 2009). It has been shown that the antioxidant efficacy of 
CeO2 NPs can be affected by incorporation of zirconium (Zr) in the CeO2 lattice (Tsai et al. 
2008). However, whilst research has been devoted since many years to elaborate on 
neuroprotective and potential anti-neurodegenerative effects of CeO2 (Singh, Cohen, and 
Rzigalinski 2007), adverse effects on the brain should also be considered for this type of 
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nanoparticles as indicated e.g. from intravenous application studies in rats (Hardas et al.     
2010; Hardas et al.     2014) and in vitro neuronal activity experiments with primary rat cortex 
cultures (Strickland et al.     2016). 
 Given that free radicals play a prominent role in the pathology of many neurological 
diseases, we explored the neurotoxicity of CeO2 NPs doped with varying amounts of Zr 
following inhalation exposure in three different mouse models, i.e. C57BL/6J, 5xFAD and 
ApoE-/- mice. The 5xFAD transgenic mice were used in this study as a model for AD. The 
5xFAD mouse model was used in a previous study, in which we have demonstrated that 
inhalation exposure to diesel engine exhaust results in an accelerated formation of Aβ-plaques 
as well as motor function impairment (Hullmann et al. 2017). Diesel engine exhaust 
represents a major source of unintentionally generated NPs in most urban environments and 
therefore supports the selection of the 5xFAD model for the investigation of the neurological 
effects of engineered NPs after inhalation. The nontransgenic littermate controls of the 
5xFAD mice (C57BL/6J background) were used as a healthy mouse model. Finally, 
apolipoprotein E-deficient (ApoE-/-) mice, subjected to a high-fat diet, were included in 
present study. ApoE-/- mice represent a well-established model for the study of 
atherosclerosis, a disease characterized by the build-up of lipid- and inflammatory cell-rich 
plaques within arteries, which underlies the majority of cardiovascular diseases (Cassee et al. 
2012; Miller et al. 2013). Since this ApoE deficiency compromises the blood brain barrier 
(Methia et al. 2001) this model could also be useful to study the susceptibility to NP-induced 
neurological effects. The adverse cardiovascular effects of diesel exhaust particles as well as 
specific types of engineered NPs have been clearly demonstrated in ApoE-/- mice in several 
studies (Hansen et al. 2007; Kang et al. 2011; Miller et al. 2013). Interestingly, a comparative 
inhalation study with engine exhausts generated using fuels with or without added CeO2 NPs 
in ApoE-/- mice revealed differences in atherosclerotic plaque formation but also in pro-
inflammatory responses in (sub)cortical brain regions (Cassee et al. 2012; Lung et al. 2014), 
which could reflect a direct effect of these redox active NPs on the central nervous system. 
The aim of the current study was to evaluate the potential neurotoxic and 
neurodegenerative effects of CeO2 NPs in mice following a four-week inhalation exposure 
and to assess the influence of redox activity by the concurrent evaluation of CeO2 NPs with 
different Zr-doping grades. The investigations formed part of a large study conducted in to 
explore the (patho)physiological effects of NP exposure on multiple organ systems in various 
mouse models (Dekkers et al. 2017; Dekkers et al. 2018). 
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2. METHODS 
 
2.1 Animals.  
In this study, three different mouse models were used. The 5xFAD transgenic mice were used 
as a model for AD. Only the female mice were used for the study in view of the reported sex-
specific differences in age- and treatment related Aβ development (Devi et al. 2010). The 
5xFAD mice overexpress the 695 amino acid isoform of the human amyloid precursor protein 
(APP695) carrying Swedish (K670N), London (V717I) and Florida (I716V) mutations as well 
as the human PS1 (M146L; L286V) mutations (Oakley et al. 2006; Ohno et al. 2004). The 
mice develop a specific phenotype that includes high APP expression levels, amyloid 
deposition (beginning at two months of age) and memory impairments and motor deficits 
(Oakley et al. 2006; Jawhar et al. 2012). The breeding was performed by mating heterozygote 
transgenic founders with C57BL/6J wild-type mice. The nontransgenic female littermates 
were used as model of healthy mice in this study. The 5xFAD and C57BL/6J mice originated 
from Jackson Laboratories. For the study, female 5xFAD mice (n=64) and female cross bred 
C57BL/6J littermates (n= 40) were used at the age of 8-11 weeks. As a third model, ApoE-/- 
mice were used. Female ApoE-/- mice (n=32) were obtained from Taconic, Denmark at age 
10–12 weeks at the beginning of the study. The four-week inhalation exposure protocol in the 
ApoE-/- mice was integrated into an 8-week high-fat (Western diet) feeding regime (Purified 
Diet Western 4021.06, ABdiets, Woerden, The Netherlands), which has been shown to 
generate complex atherosclerotic plaques with many of the hallmarks of the human disease in 
specific arterial locations (Cassee et al. 2012; Miller et al. 2013; Dekkers et al. 2017). All 
mice were barrier maintained and housed in a single room in macrolon cages. Temperature 
and relative humidity were controlled at 22±2°C and at 40-70%, respectively. Lighting was 
artificial with a sequence of 12 hours light (during daytime) and 12 hours dark (at night). Feed 
and drinking water were provided ad libitum from the arrival of the mice until the end of the 
study, except during exposure. The study was conducted at Intravacc (Bilthoven, The 
Netherlands) under a protocol approved by the Ethics Committee for Animal Experiments of 
the RIVM and performed according to applicable national and EU regulations. 
 
2.2 Inhalation study design.  
The mice were exposed via nose only inhalation to CeO2 NPs with varying amounts of Zr-
doping (0%, 27% or 78% Zr) or clean air, respectively, over a four-week period (4 mg/m3 for 
3 h/day, 5 days/week). The number of animals per treatment group designed for the present 
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study was n=10 for the C57BL/6J mice, n=16 for the 5xFAD mice and n=8 for the ApE-/- 
mice. For three mice data could not be obtained because of their early removal from the study 
for humane reasons not related to the toxicity of the NP exposure. Combined with the 
genotyping verification, this resulted in the following animal numbers per group: ApoE-/-: 
control (n=8); CeO2 (n=7); 27% ZrO2-doped CeO2 (n=8); 78% ZrO2-doped CeO2 (n=8). 
5XFAD: control (n=16); CeO2 (n=14); 27% ZrO2-doped CeO2 (n=16); 78% ZrO2-doped 
CeO2 (n=16). Wt: control (n=10); CeO2 (n=10); 27% ZrO2-doped CeO2 (n=10); 78% ZrO2-
doped CeO2 (n=10). On day 52 and day 53 after the first exposure day behaviour tests were 
performed with the mice to assess for exposure-related neurotoxic effects. The animals were 
killed on day 57. The 4-week post-exposure period was included in the study design to 
address persistency of the effects and for the compromised mouse models to develop their 
respective disease phenotypes, i.e. Aβ formation in the brains of the 5xFAD mice and the 
atherosclerotic plaques in the ApoE-/- mice. 
 
2.3 Nanomaterial production, characterization and inhalation exposure.  
Production and detailed characterization of CeO2 NPs doped with different amounts of ZrO2 
(ZrO2 contents in the doped NPs were 0 mol%, 27 mol% and 78 mol%) is described 
elsewhere (Dekkers et al. 2017). Approximately one week before the four-week exposure 
period, 20 samples of each NP (one for each day) were prepared at a concentration of 1 
mg/mL from the stock dispersions (20, 20 or 29 mg/mL for 0%, 27% and 78% ZrO2-doped 
CeO2 NPs, respectively) by diluting with ultrapure water. Before use, stock and sample 
dispersions were sonicated for 5 minutes in an ultrasonic bath (Branson CPX2800, 40 kHz, 
110W) before use to re-disperse any possible agglomerates. Aerosols of NPs were freshly 
generated using a spray nozzle technique, diluted with pressurized, clean and particle-free air, 
and heated to 24-25°C (for detailed description see (Dekkers et al. 2017). Control animals 
were exposed to 3-h filtered air under the same exposure conditions (i.e. nose-only tubes) for 
the same amount of time. Prior to the day of exposure start all animals were trained to get 
used to the nose-only inhalation tubes.  
  
2.4 Behaviour tests.  
At day 52 and 53 (i.e. 24 and 25 days after the last exposure day) the mice were examined by 
means of behavioural tests. At least 1 hour before behavioural testing, mice were placed in the 
test room for acclimatisation. All tests were performed in dim red light. All test equipment 
and mazes were cleaned with 70% ethanol prior to each test to avoid odour recognition. On 
7 
 
day 52, a string suspension test was performed: as a test of agility and grip strength (Miquel 
and Blasco 1978), a 3 mm thick, 35 cm long cotton string was stretched between two escape 
platforms on top of two vertical poles. The mice were permitted to grasp the central part of 
the string by their forepaws, released immediately thereafter and allowed to escape to one of 
the platforms. A rating system from 0 to 7 was used during a single 60 seconds trial to assess 
each animals´ performance (Moran et al. 1995) with the following modifications.  Score: 0, 
unable to hang on the string; score 1, hangs only by forepaws; score 2, attempting to climb the 
string; score 3, climbing the string with four paws successfully; score 4, moving laterally 
along the string; score 5, escaping to the end of the string; score 6, falls while trying to climb 
the platform, score 7, reaches the platform.  
On day 53, the X-maze task was performed to reflect activity and spatial working memory of 
mice by spontaneous alternation. Spontaneous alternation in rodents is based on the 
willingness to explore; a mouse tends to rotate in their entries between the four arms arranged 
in 90° position extending from a central space, which makes it more discriminative (arm 
sizes: 30 cm length, 8 cm width and 15 cm height). During 5 min test sessions, each mouse 
was placed in one arm and was allowed to move freely through the maze. The total number of 
arm entries was recorded using an infrared beam video camera during the 5 min interval to 
evaluate exploratory motor activity and this was then combined with the alternation to assess 
spatial working memory. Alternation was defined as successive entries into the four arms in 
overlapping quadruple sets (for example 1, 2, 3, 4 or 2, 3, 4, 1 but not 3, 2, 1, 3). Mice with 
impaired working memory will not remember visited arms leading to a decrease in 
spontaneous alternation (Holcomb et al. 1999). A successful entry was defined as a mouse 
entering one arm with all four paws.  The alternation percentage was calculated as % of the 
actual alternations to the possible arm entries. 
 
2.5 Necropsy and immunohistochemical analyses of paraffin embedded slices. 
At day 57, the mice were anesthetized with a mixture of ketamine and xylazine. The right 
brain hemispheres of 5xFAD mice were stored in 4% PFA for later processing for 
immunohistochemistry. The left brain hemispheres of C57/BL6, ApoE-/- and 5xFAD animals 
were rapidly dissected into cortex, olfactory bulb, cerebellum and midbrain. All brain regions 
were immediately transferred in liquid nitrogen and stored at -80°C until further processing 
for Western blotting (see below). Dehydration was performed in a series of ethanol 
concentrations, followed by a transfer into xylene. Subsequently, the brains were embedded in 
paraffin. Four µm thick paraffin sections were cut using a sliding microtome and transferred 
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on Superfrost Ultra Plus object slides (Thermo Scientific) and dried over night at 40°C. 
Subsequently, sections were deparaffinised in xylene, followed by rehydration in a series of 
ethanol (100%, 96%, 70%) and blocking of endogenous peroxidase by treatment with 0.3% 
H2O2 in PBS. Antigen retrieval was performed by boiling sections in 10 mM citrate buffer, 
pH 6.0 followed by incubation for 3 min in 88% formic acid. Non-specific antibody binding 
was blocked via incubation in 10% fetal calf serum (FCS) and 4% skimmed milk in 0.01 M 
PBS. Thereafter, slides were incubated overnight with primary anti human Aβ 42 antibody 
(clone G2-11, Cat.N0. MABN12, Merck Millipore, Darmstadt, Germany diluted 1:1000 in 
0.01 M PBS and 10% FCS in a humid chamber at room temperature. After washing slices 
were incubated with a biotinylated anti-mouse secondary antibody (dilution 1:200 in 0.01M 
PBS and 10% FCS), and the signal was visualised avidin-biotin-complex-method (ABC) by a 
Vectastain kit (Vectorlabs, Burlingame, USA) using diaminobenzidine (DAB, Sigma-Aldrich, 
Deisenhofen, Germany)) as chromogen and Hematoxylin for nuclear counterstaining. Light 
microscope images from cortex and hippocampus were taken with 100x or 50x magnification, 
respectively, using a Zeiss Axiophot microscope equipped with AxioCam MRc (Carl Zeiss, 
Jena, Germany). Quantitative Aβ42 plaque analyses were performed via calculation of the 
percentage of total amyloid plaque load in the analysed area of the section. Plaque load was 
determined using ZEN 2011 image processing software (Zeiss) after a fixed adjustment of 
contrast threshold for stained Aβ42 plaques. Plaque load was interactively determined in the 
whole hippocampal area as well as in a defined cortex region. From each animal, three brain 
slides with an interspace of approximately 30 µm were analysed. For the immunostaining of 
ionized calcium-binding adapter molecule 1 (Iba-1), brain sections were incubated overnight 
with Iba-1 antibody (Cat No. GTX100042, GeneTex; dilution 1:1000 in 0.01 M PBS and 10% 
FCS) at 4°C. The next day, slides were washed and incubated for 45 min at RT with 
biotinylated secondary antibody (dilution 1:200 in 0.01M PBS and 10% FCS. Staining was 
visualized using the ABC Vectastain kit (Vectorlabs, Burlingame, USA) and 
diaminobenzidine (DAB, Sigma-Aldrich, Deisenhofen, Germany)) as chromogen and 
Hematoxylin for nuclear counterstaining. Light microscope images from cortex and 
hippocampus were taken with 200x magnification using a Zeiss Axiophot microscope 
equipped with AxioCam MRc (Carl Zeiss, Jena, Germany). Iba-1 area (%) was quantified 
using ZEN 2011 image processing software (Zeiss) via calculation of the positive stained 
microglia (brown colour) in the defined cortical and hippocampal area. 
 
2.6 Western blot analyses.   
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Protein expression of Iba-1, glial fibrillary acidic protein (GFAP), nuclear factor E2-related 
factor 2 (Nrf2) and heme oxygenase-1 (HO-1) was evaluated by Western blot to address 
whether the exposures to the CeO2 NPs resulted in neuroinflammation and oxidative stress.  
Iba-1 and GFAP represent well-established markers of activated microglia (Kovacs 2017; 
Sasaki et al.     2001) and mature astrocytes in neuroinflammation (Li et al.     2020; 
Sofroniew and Vinters 2010), respectively. The transcription factor Nrf2 is a master regulator 
of cellular responses to oxidants via its activation of oxidative stress response genes including 
HO-1. Both Nrf2 and HO-1 are implicated in neurotoxicity and neurodegenerative diseases 
including AD (Kanninen et al.     2009; Sandberg et al.     2014; Schipper et al.     2019). For 
the analysis of these markers, cortex brain tissues were homogenized in ~5 volumes of ice-
cold RIPA buffer for 2 h in a potter tissue grinder. The total protein level was evaluated with 
the BCA kit (Thermo) according to the manufactures protocol. Equal amounts of protein (50 
µg) were loaded on a 4-12% precast NUPAGE gel (Invitrogen) and separated at 180 V in a 
Mini-PROTEAN II tank (BIO-RAD). The proteins were blotted at 250 mA for 45 min in a 
Mini Trans-Blot tank (BIO-RAD) on a 0.45 µm pore diameter nitrocellulose transfer 
membrane (Whatman, Schleicher & Schuell). With 5% milk in PBS-T (0.01 M PBS and 0.05 
% Tween-20) unspecific protein bounds were blocked for 60 min. After the blocking, the 
membrane was incubated with the primary antibody: GFAP (Cat No. ab7260, Abcam, 
1:5000), Iba-1 (Cat No. GTX100042, Gentex, 1:1000), HO-1 (Cat No. AB1284, Merck, 
1:1000), Nrf2 (C-20) (Cat No. sc-722, Santa Cruz,1:500) overnight at 4°C. Next day, 
secondary hrp-conjugated antibody and β-Actin-hrp (AC-15) (Cat No. A384, Sigma,1:50000) 
was incubated for 1 h at room temperature. Detection of proteins was performed with ECL 
solution (GE Healthcare) and visualized with CHEMI Premium Imager (VWR). With the use 
of ImageJ software (National Institutes of Health, Bethesda, USA) quantification of protein 
expression was evaluated relative to β-actin protein level. 
 
2.7 Statistical analyses.   
Data were analysed using IBM-SPSS (version 22) and are expressed as mean ± SEM unless 
stated otherwise. Data were evaluated by one-way analysis of variance (ANOVA) with 
Dunnett post-hoc analysis using the air exposed animals as statistical control group. 
Differences were considered statistically significant at p < 0.05.  
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3 RESULTS 
 
3.1 Exposure conditions 
Detailed characteristics of NPs and their particle size distributions, mass and number 
exposure concentrations as well as lung deposited dose estimations for the inhalations are 
described in detail elsewhere (Dekkers et al. 2017; Dekkers et al. 2018). Briefly, the different 
CeO2 particles had a primary particle size of 4.7 ± 1.4 nm. The gravimetric mass 
concentrations and size distribution of the aerosols were almost identical for the exposures to 
the CeO2, 27% Zr-doped CeO2 and 78% Zr-doped CeO2 NPs. 
 
3.2 Effects on motor activity and cognitive function 
The effect of exposure to redox-modified CeO2 NPs on the behaviour of the mice was 
determined using the string suspension test and the X-maze test. The string suspension task 
was used to assess for motor activity, where mice were allowed to grasp a cotton string 
stretched between two vertical poles and the ability of the animals to cling on and move to 
one of the platforms on top of the poles within 60 seconds was measured and scored. Results 
are shown in figure 1.  
 
There was no significant difference in test performance between the controls (clean air 
exposed mice) of the three different strains. Exposure of the mice with the distinct CeO2 NPs 
did not affect the performance of the C57BL/6J mice and the 5xFAD transgenic mice in the 
string suspension task. However, among the ApoE-/- mice the string suspension test 
performance was diminished in the group that was exposed to the 78% Zr-doped CeO2 NPs 
compared to controls, indicative of an adverse impact on the motor function (Fig. 1). The 
inhalation exposures to the CeO2 NPs that contained less (27%) or no (0%) Zr did not 
significantly alter the behaviour of the ApoE-/- mice in the string suspension test in 
comparison to the clean air exposed animals. 
 
The X-maze task was performed to assess for locomotor activity and spatial working 
memory of the mice in relation to the different inhalation exposures. The results of these 
investigations are shown in Figure 2. In contrast to the string suspension test, for this task 
some differences were already noted between the controls (clean air) of the different mouse 
models. On the one hand, for the ApoE-/- control group the total number of arm entries tended 
to be lower than for the C57BL/6J and 5xFAD controls. On the other hand, the alternation 
(%) in the test tended to be lower for the 5xFAD control mice in comparison to the C57BL/6J 
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and ApoE-/- controls. However, in both cases the observed differences were not statistically 
significant.  
 
In concordance with the string suspension task, the X-maze test also revealed a 
significant effect on behaviour following inhalation exposure to the 78% Zr-doped CeO2 NPs, 
whereas the other types of NPs showed no effects. In this case, however, the effect was seen 
in the 5xFAD mouse model: The 5xFAD mice that had been exposed to the 78% Zr-doped 
CeO2 NPs showed a significantly reduced number of total arm entries compared to the control 
5xFAD mice, indicative of a decreased exploratory motor activity for this treatment group 
(Figure 2). However, the alternation in the X-maze task, which is an indicator of the spatial 
working memory of mice, did not differ between these groups. In fact, the alternation 
percentage among the 5xFAD groups tended to be highest in the 78% Zr-doped CeO2 NPs. In 
the ApoE-/- and C57BL/6J mice, no significant treatment-related effects on locomotor activity 
and spatial working memory were found with the X-maze testing. 
 
3.3 Effects on Aβ plaque formation and markers of neuroinflammation and oxidative stress 
Histopathologically, AD is characterized by the presence of extracellular senile plaques 
and intracellular neurofibrillary tangles (Beyreuther and Masters 1991; Selkoe 2001). To 
investigate the impact of the exposure to different redox-modified CeO2 NPs on the level of 
Aβ plaque formation, parasagittal brain slices of the 5xFAD mice were stained with an 
antibody against human Aβ42, and the Aβ plaque load was determined in hippocampus and 
cortex. The results of this analysis are shown in Figure 3. There were no significant 
differences in plaque formation between the different treatment groups: the inhalation 
exposures to NPs, irrespective of their redox modification, did not result in an acceleration of 
the Aβ plaque formation in this transgenic mouse model of AD. To determine whether the 
inhalation of redox-modified CeO2 NPs affect the level of neuroinflammation in the brains of 
the 5xFAD mice, the amount of Iba-1 positive microglia cells was assessed in the same brain 
regions using immunohistochemical analysis.  Compared to the clean air exposed 5xFAD 
mice, the number of activated Iba1-positive microglia cells was not significantly altered in the 
brain of NPs treated 5xFAD mice (Fig. 4). 
To further evaluate the potential effect of the different redox-modified CeO2 NPs on 
neuroinflammation and oxidative stress, cortical brain tissues of all three mouse models were 
analysed by Western blotting for the expression of Iba-1 and GFAP as well as Nrf2 and HO-
1, respectively. Results for Iba-1 and GFAP are shown in Figure 5. As can be seen in the 
figure, the Western blot analyses for Iba-1 confirmed the absence of treatment-related changes 
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in abundance of Iba-1 positive microglia cells in the 5xFAD mice by immunohistochemistry: 
No significant differences Iba-1 protein levels were detected in the 5xFAD mice in 
association with the CeO2 inhalation exposures. Likewise, the protein levels of Iba-1 were not 
significantly altered in the brains of the C57BL/6J and ApoE-/- mice. Next, the protein level of 
the astrocyte marker GFAP was analysed. In the ApoE-/- and 5xFAD mice, no treatment 
related effects on GFAP protein level could be observed. Interestingly, however, the 
C57BL/6J mice exposed to the 78% Zr-doped CeO2 NPs displayed significant higher GFAP 
levels whereas inhalation of both other types of NPs showed no effect. 
The effect of exposure to redox-modified CeO2 NPs on the protein expressions of Nrf2 
and its downstream target HO-1 are shown in Figure 6. Inhalation exposure to the NPs, 
irrespective of their redox-modification, did not affect the level of Nrf2 or HO-1 in the brains 
of C57BL/6J, ApoE-/- and 5xFAD mice (Fig. 6). In the 5xFAD mice, a tendency of increasing 
Nrf2 protein levels with increased Zr-doping was noted suggestive of increasing oxidative 
stress response. However, the observed differences were not statistically significant and were 
also not further substantiated by the HO-1 findings for the same mice. 
 
 
4 DISCUSSION 
 
The experiments performed in this study formed part of a large study to assess the influence 
of redox activity on the toxicity of inhaled CeO2 NPs in mice, by comparison of the effects of 
different quantities of Zr-doping. Detailed physicochemical and exposure characteristics of 
the NPs as well as the pulmonary and cardiovascular findings in the exposed mice have been 
published in a separate paper (Dekkers et al. 2017). In all three mouse models (C57BL/6J, 
5xFAD, ApoE-/-) the four-week inhalation exposures were without any major toxicological 
effects in the lungs. In the ApoE-/- mouse model of vascular disease, the inhalation exposures 
to the NPs did not cause a statistically significant change in the overall size of atherosclerotic 
plaques. However, there was a trend towards an increased inflammatory cell content (i.e. 
macrophage-derived foam cells) in the plaques with the inhalation of CeO2 NPs with 
increasing ZrO2 content (Dekkers et al. 2017). 
In the present study, we evaluated whether inhalation exposure to these NPs could also 
cause neurotoxicity and promote AD. Therefore, mouse behaviour tests were performed in all 
the three mouse models to explore effects on motor activity and cognitive function. Brain 
tissue protein levels of HO-1, Nrf2, Iba-1 and GFAP were measured to address the role of 
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oxidative stress and neuroinflammation. The potential effects of the inhaled CeO2 NPs on 
amyloid-β plaque formation were assed in the 5xFAD mouse model. In this study, we could 
observe specific effects that were dependent on the mouse model as well as the NP 
modification. While the behaviour effects were observed in both compromised mouse models, 
increase protein levels of GFAP were found only in the healthy C57BL/6J mice. These 
significant effects were observed exclusively for the CeO2 NPs that were doped with the 
highest amount of Zr (78%). In the ApoE-/- mice, the four-week inhalation exposure to these 
specific NPs resulted in a significantly diminished performance in the string suspension test. 
Such effect could be an indication of a greater susceptibility to an impaired forced motor 
performance in this mouse model of vascular disease. In the 5xFAD mice, the exposure to the 
78% Zr-doped CeO2 NPs resulted in a significant reduction of the total of arm entries in the 
X-maze task. This latter effect suggests a possible reduction in explorative locomotor activity 
for this mouse model of AD. However, alternation behaviour in the X-maze test, which is an 
indicator of cognitive performance, was not impaired in same treatment group. 
Interestingly, while the motor performance effects on behaviour were observed with 
the two disease models, no behavioural effects were seen in the healthy (C57BL/6J) mice. 
Rodent models of susceptibility and disease are being increasingly used in toxicological 
studies exploring air pollution to better understand the underlying mechanisms (Oberdorster, 
Oberdorster, and Oberdorster 2005; Stone et al. 2017). In line with our present findings with 
the Zr-doped CeO2 NPs, impaired motor performance was observed following diesel engine 
exhaust inhalation exposure in 5xFAD mice but not in their wildtype littermates (Hullmann et 
al. 2017). Studies with diesel exhaust particles in high-fat fed ApoE deficient mice have also 
demonstrated the value of this susceptibility model over wildtype mice to support the 
epidemiological evidence that links exposure to airborne particles to cardiovascular disease 
(Miller et al. 2013). Interestingly, the behaviour changes in the two compromised mouse 
models were exclusively seen with the highest Zr-doped CeO2, indicating that these effects 
appear to depend on the redox-activity of the inhaled NPs. The introduction of Zr into the 
crystalline structure of CeO2 NPs is considered to enhance their antioxidant properties (Tsai et 
al. 2008). As such, one would have expected a possibly protective effect for the undoped 
CeO2 NPs. However, our present findings are in line with the previously reported effects of 
the inhalation exposures on the inflammatory content of atherosclerotic plaques in the ApoE-/- 
mice, which revealed an increased presence of macrophage-derived foam cells for CeO2 NPs 
with increasing Zr content (Dekkers et al. 2017). 
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 Behaviour tests form an important component of neurotoxicity testing (Moser 2011; 
OECD 1997). It is therefore tempting to speculate that the observed motor performance 
effects in the ApoE-/- and 5xFAD mice result from a direct neurotoxic effect of the high Zr-
doped CeO2 NPs. Indeed, several studies that have explored the pulmonary toxicity of NPs, 
including CeO2, indicate that their adverse effects are driven by oxidative stress and 
inflammation (Unfried et al.     2008; Morimoto et al.     2016; Stone et al.     2017; Schwotzer 
et al.     2018). However, in our present inhalation study we found no significant treatment 
related changes in HO-1 or Nrf2 for all three mouse models. In contrast, Hardas and 
colleagues observed increased HO-1 in rat brain upon intravenous administration of CeO2 
NPs (Hardas et al.     2014). The fundamental differences in exposure route and dose offer a 
plausible explanation for these contrasts. The brains of ApoE-/- and 5xFAD mice in our 
inhalation study also did not display significant treatment related changes in protein levels of 
Iba-1 and GFAP, even for the groups that were exposed to the 78% Zr-doped CeO2 NPs. 
Taken together, this suggests that the motor function effects which we observed in both 
compromised mouse models were not mediated by local oxidative stress and 
neuroinflammation. 
Surprisingly, however, increased protein levels of GFAP were observed in the cortex 
of the healthy C57BL/6J mice, the only mouse model that did not show significant changes in 
(motor function) behaviour. On the one hand, this adds further support to the absence of a 
mechanistic link between neuroinflammation and motor activity changes for inhaled CeO2 
NPs. On the other hand, the finding again indicates the importance of the redox-properties of 
CeO2 NPs, as the effect on GFAP was only seen with the particles that were doped with the 
highest amount of Zr (78%). Increased GFAP levels were previously also found in rat brain 
following repeated inhalation exposures to steel welding fumes (Antonini et al.     2009). In 
contrast to our findings, increased GFAP levels were observed in ApoE-/- mice after long term 
inhalation of ambient ultrafine particles (Kleinman et al.     2008). In another study with in 
C57BL/6 mice, the long term inhalation of fine (µm size mode) ambient particulate matter 
(PM2.5) did not cause significant changes in brain levels of GFAP and Iba-1 (Bhatt et al.     
2015). 
The ApoE-/- mice were selected a priori for the investigation of cardiovascular effects 
following NP inhalation exposure, however, due to the logistical requirements of the 
extensive tissue collection, we were unable the further evaluate the brain tissue from these 
mice by immunohistochemistry (Dekkers et al. 2017). However, the brains of the 5xFAD 
mice were prioritised to address the potential impact of (undoped and Zr-doped) CeO2 NPs on 
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the development of the neurodegenerative processes. Previously, we demonstrated an 
accelerated amyloid plaque load formation (whole brain Aβ42 protein levels) in 15 week old 
female 5xFAD mice following a three-week diesel engine exhaust inhalation exposure (0.95 
mg/m3, 6 h/day, 5 days/week) (Hullmann et al. 2017). In the present study, however, we did 
not observe a significant alteration in the β-amyloid pathology in the brains of 5xFAD 
animals following four-week inhalation exposure to the (Zr-doped) CeO2 NPs (4 mg/m3 for 3 
h/day, 5 days/week). Moreover, in alignment with the Western blot findings, the brains of the 
5xFAD mice did not reveal significant differences in immunostaining of Iba-1. Combined 
with the observed absence of (cognitive) behaviour changes in the 5xFAD mice, these data 
argue against the hypothesis that CeO2 NPs may promote AD pathology in association with 
their redox-activity. The motor performance changes observed to NPs in the ApoE-/- and 
5xFAD mice may not necessarily be related to a direct neurotoxic effect in isolation, but 
instead due to indirect effects, or alternatively, a result of an interaction between the exposure 
and increased susceptibility of both disease models. Age related changes in motor 
performance are well-described in the 5xFAD mouse model (Jawhar et al. 2012; O'Leary et 
al. 2018) and have also been reported for the ApoE-/- mice (Raber et al. 2000; Zerbi et al. 
2014). Importantly, however, we did not observe statistically significant differences in 
behaviour test performance of the (clean air exposed) control mice between the three different 
mouse modes. This indicates that there was no major behaviour impairment per se in the two 
mouse disease models, and also suggests that it is unlikely that the effects of NPs on ApoE-/- 
mice were principally due to the high-fat diet fed to the mice. Further research is needed to 
verify the potential adverse impact of inhaled CeO2 NPs on motor function and to unravel the 
mechanism that could explain the redox-involvement for these metal oxide NPs. 
Up to now, there is only very limited data about the potential neurotoxic effects of 
CeO2 NPs in association with inhalation exposure. A recent study showed that female ICR 
mice exposed to CeO2 particles (intranasal instillation, daily dose of 40 mg/kg body weight) 
of varying sizes (i.e. 35 nm, 300 nm and >1 µm) displayed significantly increased GFAP 
expression in the hippocampus and olfactory bulb. The authors claim that intranasal 
instillation of CeO2 particles induced damage within the olfactory bulb and hippocampus, but 
that particle size does not play a major role in the observed adverse responses (Liu et al. 
2016). Nemmar and colleagues reported increased levels of the inflammatory cytokine Tumor 
Necrosis Factor-α, reactive oxygen species and DNA damage in the brains of mice by CeO2 
NPs, 24 hours after a single intratracheal instillation (0.5 mg/kg) (Nemmar et al. 2017). 
However, for the aforementioned studies the observed effects require perspective on the 
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method and site of administration in the respiratory tract for the CeO2 particles, when 
compared to the outcomes of our present controlled inhalation exposure study. This relates to 
the obvious differences in dose and dose-rate of the NPs (i.e. bolus application versus 
inhalation) as well as to the regional deposition in the respiratory tract organ (i.e. nasal versus 
alveolar). 
 
 
5 CONCLUSIONS 
 
We have investigated the neurological effects of redox-modified CeO2 NPs using varying 
levels of Zr-doping (0 %, 27% and 78%), after four-week inhalation exposures in three 
different mouse models. Our study findings reveal that the subacute inhalation exposure to 
CeO2 NPs did not cause major cognitive behavioural impairments in mice or promote 
amyloid-β plaque formation and neuroinflammation in the 5xFAD transgenic mouse model of 
AD. However, motor performance changes were observed both in the 5xFAD and ApoE-/- 
mice for the CeO2 NPs that were doped with the highest amount of Zr. In healthy C57BL/6J 
mice, the same particles caused increased GFAP levels in the absence of behaviour changes. 
The observed behavioural effects in the two compromised models were not substantiated 
further by changes in markers of neuroinflammation and oxidative stress. Therefore, further 
investigations are warranted to unravel the mechanism whereby inhaled CeO2 NPs can affect 
motor activity in a redox activity dependent manner. 
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FIGURE CAPTIONS 
 
Figure 1: Effects of redox-modified CeO2 on performance in the string suspension task. 
Female C57BL/6J (A), ApoE-/- (B) and 5xFAD (C) mice were exposed to clean air (control) 
or CeO2 and 27% ZrO2-doped CeO2 or 78% ZrO2-doped CeO2 NPs via inhalation. The ability 
of the mice to escape to a platform within 60 seconds was measured and transferred to a 
rating system from 0 to 7 whereby a higher score represents a better performance. Data are 
expressed in mean ± SEM, *statistical significantly different from the respective control in 
Dunnet post-hoc test following one-way ANOVA with p<0.05. Number of animals per group: 
ApoE-/-: control (n=8); CeO2 (n=7); 27% ZrO2-doped CeO2 (n=8); 78% ZrO2-doped CeO2 
(n=8). 5XFAD: control (n=16); CeO2 (n=14); 27% ZrO2-doped CeO2 (n=16); 78% ZrO2-
doped CeO2 (n=16). C57/Bl6J control (n=10); CeO2 (n=10); 27% ZrO2-doped CeO2 (n=10); 
78% ZrO2-doped CeO2 (n=10). 
 
Figure 2:  Effects of redox-modified CeO2 on performance in the X-maze task. 
Female C57BL/6J (A, D), ApoE-/- (B, E) and 5xFAD (C, F) mice were exposed to clean air 
(control) or CeO2 and 27% ZrO2-doped CeO2 or 78% ZrO2-doped CeO2 NPs via inhalation. 
After this treatment, the differently exposed groups were subjected to the X-maze task. Mice 
were place in the maze for 5 minutes. The behavioural parameters analysed were total arm 
entries (A, B, C) and alternation (D, E, F) and expressed in mean ± SEM. *Statistical 
significance different from the respective control in Dunnet post-hoc test following one-way 
ANOVA with p<0.05. Number of animals per group: ApoE-/-: control (n=8); CeO2 (n=7); 
27% ZrO2-doped CeO2 (n=8); 78% ZrO2-doped CeO2 (n=8). 5XFAD: control (n=16); CeO2 
(n=15); 27% ZrO2-doped CeO2 (n=16); 78% ZrO2-doped CeO2 (n=16). C57/Bl6J:  control 
(n=10); CeO2 (n=10); 27% ZrO2-doped CeO2 (n=10); 78% ZrO2-doped CeO2 (n=10). 
 
Figure 3: Effect of redox-modified CeO2 NPs inhalation on β-Amyloid pathology in 
5xFAD mice.  
Aβ plaque load was determined in parasagittal brain slices of 5xFAD mice after exposure to 
clean air (control n=16), CeO2 (n=15), 27% ZrO2-doped CeO2 (n=16) or 78% ZrO2-doped 
CeO2 (n=16) NPs. Aβ42 was visualized by IHC in 4 µm sections of paraffin-embedded brain 
hemispheres (Representative pictures are shown in A). For quantification, plaque load was 
determined in the hippocampus (B) and in the cortex (C) using image analysis software and 
calculated as the percentage area occupied by Aβ immunostaining expressed in mean ± SEM. 
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For determination of plaques in the cortex, whole image sections were evaluated while the 
hippocampus regions were defined by hand to evaluate only the hippocampus. A trend was 
observed of reduced Aβ plaques in the brains of mice exposed to the 78% Zr-doped CeO2 
NPs, but this effect was not statistically significant. 
 
Figure 4: Effect of redox-modified CeO2 NP inhalation on Iba-1 immunostaining in 
hippocampus and cortex of 5xFAD mice. 
Parasagittal brain slices of 5xFAD mice exposed to clean air of CeO2 NPs with different 
doping of Zr (n=6 per group), were stained with an antibody against Iba-1 to detect activated 
microglia (representative pictures are shown in A). For quantification, Iba-1 stain was 
determined in (B) CA1/subiculum of the hippocampus (200-fold microscopic magnification) 
and (C) cortex layer 5 (200-fold microscopic magnification) using image analysis software 
and calculated as the percentage area occupied by Iba-1 immunostaining and expressed in 
mean ± SEM. 
 
Figure 5: Effect of redox-modified CeO2 NP inhalation on Iba-1 and GFAP protein levels 
Levels of Iba-1 (B, C, D) and GFAP (E, F, G) were assessed by Western blot analysis in 
lysates of the cortex of female C57BL/6J (B, E), ApoE-/- (C, F) and 5xFAD (D, G) exposed 
to clean air or CeO2 NPs with different doping of Zr (representative blots are shown in A). 
Data were normalized to the level of β-actin and expressed in mean ± SEM. * Statistical 
significance different from the respective control in Dunnet post-hoc test following one-way 
ANOVA with p<0.05. Number of animals per group: ApoE-/-: control (n=5); CeO2 (n=5); 
27% ZrO2-doped CeO2 (n=5); 78% ZrO2-doped CeO2 (n=4). 5XFAD: control (n=4); CeO2 
(n=4); 27% ZrO2-doped CeO2 (n=4); 78% ZrO2-doped CeO2 (n=4). C57/Bl6J:  control (n=5); 
CeO2 (n=5); 27% ZrO2-doped CeO2 (n=5); 78% ZrO2-doped CeO2 (n=5). 
 
Figure 6: Effect of redox-modified CeO2 NP inhalation on Nrf2 and HO-1 protein levels 
Lysates of the cortex of C57BL/6J (B, E), ApoE-/- (C, F) and 5xFAD (D, G) mice exposed to 
clean air or CeO2 NPs with different doping of Zr were subjected to Western Blot analysis. 
Levels of Nrf2 (B, C, D) and HO-1 (E, F, G) were normalized to the level of β-actin and 
expressed in mean ± SEM. Representative blots are shown in A. Number of animals per 
group: ApoE-/-: control (n=5); CeO2 (n=5); 27% ZrO2-doped CeO2 (n=5); 78% ZrO2-doped 
CeO2 (n=4). 5XFAD: control (n=4); CeO2 (n=4); 27% ZrO2-doped CeO2 (n=4); 78% ZrO2-
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doped CeO2 (n=4). C57/Bl6J:  control (n=5); CeO2 (n=5); 27% ZrO2-doped CeO2 (n=5); 78% 
ZrO2-doped CeO2 (n=5).  
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Highlights: 
• 4-week mouse inhalation study with 0%, 27% and 78% Zr-doped CeO2 nanoparticles 
• No acceleration of Alzheimer-related features in 5xFAD mouse model 
• Motor performance changes in 78% Zr-doped CeO2 exposed ApoE-/- and 5xFAD mice 
• Increased GFAP levels in 78% Zr-doped CeO2 exposed C57BL/6J mice 
 
